| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO
1 company
Cheng Liu is CEO at ESLA. Cheng Liu's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $166K at current prices.
Cheng Liu has 2 Form 4 filings on record from October 2024 to August 2026, all as CEO at Estrella Immunopharma (ESLA), 2024–2026.
The 3 reported transactions were 2 option or other derivative awards and 1 option exercise.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria